SynthesisJournal of translational medicine2026
Therapeutic efficacy of genetically engineered neural stem cells in cerebral ischemia: a systematic review and meta-analysis.
Synthesis in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStroke is one of the most common causes of death and permanent neurological disabilities worldwide yet neuroprotective or regenerative therapies do not exist. Genetically modified neural stem cells (NSC) could help overcome key limitations of naïve or unmodified NSCs and improve therapeutic efficacy. The aim of this systematic review and meta-analysis is to evaluate existing preclinical literature using animal models to compare the therapeutic effects of genetically modified NSCs for stroke compared to naïve NSCs or vehicle control. MAIN BODY: Controlled studies investigating genetically modified NSC therapy using animal models of stroke were identified using PUBMED, Scopus and the Chinese National Knowledge Infrastructure (CNKI). Primary outcomes were lesion volume reduction and neurological functional recovery measured via Neurological Severity Score (NSS). Data for meta-analysis were synthesized and expressed as standardised mean difference (SMD) with 95% confidence intervals (CI) using inverse variance and a random effects model. Our secondary outcomes of interest included modified NSC survival, NSC differentiation into neurons, endogenous neural integration, anti-inflammatory effects and migratory capacities. Twenty-nine studies were included for systematic review, and eighteen studies were included for meta-analysis. Genetically modified NSCs significantly reduced lesion volume when compared to both naïve NSCs (SMD 1.07; 95% CI: [0.70, 1.43]; p < 0.00001) and vehicle/injury control (SMD 4.60; 95% CI: [2.69, 6.51]; p < 0.00001), and also significantly improved neurological functional recovery compared to both naïve NSCs (SMD 2.75; 95% CI: [0.34, 5.16]; p = 0.03) and vehicle/injury control (SMD 4.28; 95% CI: [0.64, 7.93]; p = 0.02).
conclusionsExisting preclinical literature suggests that genetically modified NSCs have the potential to improve therapeutic efficacy of NSCs. However, our systematic review revealed the field lacks uniformity in outcomes measured, an optimised protocol for cell therapy and absence of large animal model studies, all of which pose significant barriers to clinical translation and must be addressed for the field to progress. While we were unable to identify a clear candidate gene, our review highlights the potential for genetically modified NSCs as a future adjunct neuroprotective therapy for stroke and warrants further research in this area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.